Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AnaptysBio Inc

ANAB
Current price
21.34 USD -0.21 USD (-0.97%)
Last closed 21.27 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 601 634 496 USD
Yield for 12 month -5.45 %
1Y
3Y
5Y
10Y
15Y
ANAB
21.11.2021 - 28.11.2021

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

45 USD

P/E ratio

Dividend Yield

Current Year

+17 157 000 USD

Last Year

+10 287 000 USD

Current Quarter

+9 005 000 USD

Last Quarter

+3 318 000 USD

Current Year

+14 781 000 USD

Last Year

+7 952 000 USD

Current Quarter

+8 401 000 USD

Last Quarter

+2 726 000 USD

Key Figures ANAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -156 420 000 USD
Operating Margin TTM -386.41 %
PE Ratio
Return On Assets TTM -18.47 %
PEG Ratio
Return On Equity TTM -93.44 %
Wall Street Target Price 45 USD
Revenue TTM 17 157 000 USD
Book Value 3.31 USD
Revenue Per Share TTM 0.64 USD
Dividend Share
Quarterly Revenue Growth YOY 32.3 %
Dividend Yield
Gross Profit TTM -78 511 000 USD
Earnings Share -6.08 USD
Diluted Eps TTM -6.08 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ANAB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ANAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ANAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 13.7263
Price Sales TTM 35.4252
Enterprise Value EBITDA -1.645
Price Book MRQ 6.9077

Financials ANAB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ANAB

For 52 weeks

13.36 USD 27.5 USD
50 Day MA 23.56 USD
Shares Short Prior Month 4 135 511
200 Day MA 20.06 USD
Short Ratio 11.43
Shares Short 4 303 921
Short Percent 23.57 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics